IPOs and Catalysts/Events, Global Equity Research Ltd

Arun George

Arun has over 15 years’ experience covering the Technology sector. During this time, he has worked with technology start-ups and as an equity analyst in investment banks and independent research firms. He was formerly a Technology Analyst for Canaccord Genuity, Altium Securities, Espirito Santo Investment Bank, Noble Group and Clear Capital. He has a dual Master’s degree in Financial Engineering and Industrial and Operations Engineering from the University of Michigan. He obtained his Bachelor’s degree in Mechanical Engineering from the Indian Institute of Technology, Bombay. He is also a CFA charterholder.

IPOs and Catalysts/Events

Uncompromised, Independent, Conflict-Free Research

Global Equity Research Ltd

Global Equity Research was started in 2017 by a group of experienced research professionals. It was founded on a passionate belief in the importance and the need for uncompromised, independent, conflict-free research. We aim to provide differentiated and actionable primary and bottom up fundamental research.

Equity Capital Markets

<a href="https://www.smartkarma.com/entities/remegen-ltd" target="_blank" data-smartkarma-citation="entities:29191:1" rel="noopener">Remegen Ltd (1788976D CH)</a> is a biopharmaceutical company with a focus on the development and commercialisation of innovative and differentiated biologics for the treatment of autoimmune, oncology and ophthalmic diseases. RemeGen aims to raise proceeds of $400 million through a Hong Kong IPO, according to press reports.<div class="content-highlight">RemeGen currently has a pipeline of more than ten drug candidates. Among the drug candidates, five are in clinical development stage targeting 17 indications and more than five are in IND-filed or IND-enabling stage. The three core drug candidates are telitacept, disitamab vedotin and RC28. Overall, we believe that the prospectus RemeGen’s core drug assets are favourable. </div>

Remegen Ltd (1788976D CH) is a biopharmaceutical company with a focus on the development and commercialisation of innovative and differentiated biologics for the treatment of autoimmune, oncology and ophthalmic diseases. RemeGen aims to raise proceeds of $400 million through a Hong Kong IPO, according to press reports.RemeGen currently has a pipeline of more than ten drug candidates. Among the drug candidates, five are in clinical development stage targeting 17 indications and more than five are in IND-filed or IND-enabling stage. The three core drug candidates are telitacept, disitamab vedotin and RC28. Overall, we believe that the prospectus RemeGen’s core drug assets are favourable. 

Remegen

RemeGen IPO Initiation: Seeking a Cure